Vertaling van "likely to affect the development " (Nederlands → Frans) :

In the same train of thought, a very recent report of the Committee on Toxicity of Chemicals in Food, an independent scientific advisory body in the United Kingdom, shows the state of affairs concerning the potential toxicity of caffeine in pregnant women and affirms, with great circumspection, that caffeine is already likely to affect the development of the foetus from a daily consumption of 200 mg (COT, 2008).
Dans le même ordre d’idées, un rapport très récent du Comité de Toxicologie du Royaume-Uni, organisme indépendant de conseil scientifique, fait un nouveau point sur la possible toxicité de la caféine chez la femme enceinte et déclare, avec beaucoup de précautions, qu’il est vraisemblable que la caféine affecte le développement du fœtus déjà pour des apports journaliers de l’ordre de 200 mg (COT, 2008).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

An initiative started by the Novartis Foundation for Sustainable Development with Swiss and Swedish development agencies provides support to the Regional Psychosocial Support Initiative (REPSSI), which helps children affected by HIV/AIDS, poverty and conflict in 13 African countries.
En association avec deux organismes d’aide au développement suisse et suédois, la Fondation Novartis pour un développement durable permet de soutenir le projet REPSSI (Regional Psychosocial Support Initiative), lequel vient en aide aux enfants touchés par le sida, la pauvreté ou la guerre dans treize pays africains.

The FAMHP R&D (research and development) Department has already put a considerable amount of work into fostering collaborations like this with the Ethics Committees.
The FAMHP R&D (research and development) Department has already put a considerable amount of work into fostering collaborations like this with the Ethics Committees.

Those who are separated or widowed appear to be more likely to develop mood disorders.
Les sujets séparés et les veufs/veuves s’avèrent plus susceptibles de développer des troubles de l’humeur.

It refers to a specific state characterised by the vulnerability and the psychic changes that affect these individuals during this period of self-development.
Elle représente cet état spécifique de fragilité et de changements psychiques qui s’opèrent à cette période du développement de soi et qui fragilise l’individu en devenir.

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.